Banque Pictet & Cie SA Boosts Stake in Qiagen N.V. (NYSE:QGEN)

Banque Pictet & Cie SA grew its stake in Qiagen N.V. (NYSE:QGEN - Free Report) by 20.7% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 86,207 shares of the company's stock after acquiring an additional 14,792 shares during the period. Banque Pictet & Cie SA's holdings in Qiagen were worth $3,415,000 at the end of the most recent reporting period.

A number of other hedge funds have also added to or reduced their stakes in the stock. Brown Brothers Harriman & Co. purchased a new stake in shares of Qiagen in the 4th quarter worth approximately $37,000. EverSource Wealth Advisors LLC lifted its position in Qiagen by 152.5% during the fourth quarter. EverSource Wealth Advisors LLC now owns 871 shares of the company's stock valued at $39,000 after acquiring an additional 526 shares during the last quarter. Tower Research Capital LLC TRC lifted its position in Qiagen by 770.6% during the fourth quarter. Tower Research Capital LLC TRC now owns 2,490 shares of the company's stock valued at $111,000 after acquiring an additional 2,204 shares during the last quarter. GAMMA Investing LLC lifted its position in Qiagen by 93.9% during the first quarter. GAMMA Investing LLC now owns 2,943 shares of the company's stock valued at $118,000 after acquiring an additional 1,425 shares during the last quarter. Finally, Globeflex Capital L P purchased a new stake in Qiagen during the fourth quarter valued at approximately $151,000. 70.00% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

QGEN has been the subject of a number of analyst reports. Robert W. Baird increased their target price on shares of Qiagen from $42.00 to $43.00 and gave the company a "neutral" rating in a research report on Monday, April 21st. Barclays started coverage on shares of Qiagen in a research report on Tuesday, June 24th. They set an "overweight" rating and a $55.00 target price for the company. Wall Street Zen raised shares of Qiagen from a "buy" rating to a "strong-buy" rating in a report on Thursday, May 15th. Bank of America raised their price target on shares of Qiagen from $50.00 to $53.00 and gave the stock a "buy" rating in a report on Thursday, June 26th. Finally, Redburn Atlantic cut shares of Qiagen from a "buy" rating to a "neutral" rating in a report on Friday, April 4th. Seven investment analysts have rated the stock with a hold rating, three have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of "Hold" and a consensus target price of $49.40.

Qiagen Stock Performance

Shares of NYSE:QGEN traded down $0.57 during midday trading on Friday, reaching $47.99. The company's stock had a trading volume of 918,565 shares, compared to its average volume of 1,339,827. The firm has a market capitalization of $10.67 billion, a PE ratio of 120.31, a P/E/G ratio of 2.44 and a beta of 0.68. Qiagen N.V. has a twelve month low of $37.63 and a twelve month high of $49.30. The stock has a fifty day moving average of $45.27 and a 200 day moving average of $42.80. The company has a quick ratio of 2.83, a current ratio of 3.37 and a debt-to-equity ratio of 0.40.

Qiagen (NYSE:QGEN - Get Free Report) last released its quarterly earnings results on Wednesday, May 7th. The company reported $0.55 EPS for the quarter, beating the consensus estimate of $0.50 by $0.05. The company had revenue of $483.46 million for the quarter, compared to analyst estimates of $465.66 million. Qiagen had a net margin of 4.68% and a return on equity of 14.61%. The firm's revenue was up 5.2% on a year-over-year basis. During the same quarter last year, the business earned $0.44 earnings per share. On average, equities analysts expect that Qiagen N.V. will post 2.26 EPS for the current fiscal year.

Qiagen Announces Dividend

The business also recently announced a dividend, which was paid on Thursday, July 10th. Stockholders of record on Thursday, July 3rd were given a $0.25 dividend. The ex-dividend date of this dividend was Wednesday, July 2nd. This represents a dividend yield of 0.52%. Qiagen's dividend payout ratio (DPR) is 62.50%.

Qiagen Company Profile

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.